XML 13 R7.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net income $ 395,917 $ 387,859
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization expense 436,217 427,285
Impairment of long lived assets 8,845 27,727
Reduction in carrying value of operating right-of-use assets 33,979 35,238
Loss on equity method investments 383 2,643
Acquisition-related gain (6,160) 0
Charge on cash flow hedge 3,335 0
Amortization of financing costs and debt discount 12,485 13,544
Stock compensation expense 47,303 55,703
Deferred taxes (114,487) (126,620)
Foreign exchange movements (7,670) (52,334)
Other non-cash items 21,966 18,595
Changes in operating assets and liabilities:    
Accounts receivable (139,096) (140,760)
Unbilled revenue 14,370 (221,104)
Unearned revenue 158,269 28,352
Other net assets (144,760) 166,613
Net cash provided by operating activities 720,896 622,741
Cash flows from investing activities:    
Purchase of property, plant and equipment (87,980) (85,145)
Purchase of subsidiary undertakings (5,100) 0
Sale of available for sale investments 1,611 0
Purchase of available for sale investments (1,852) 0
Purchase of investments in equity - long term (10,829) (1,840)
Net cash used in investing activities (104,150) (86,985)
Cash flows from financing activities:    
Drawdown of bank credit lines and loan facilities 305,000 25,000
Repayment of bank credit lines and loan facilities (930,000) (625,000)
Proceeds from exercise of equity compensation 36,517 28,967
Share issue costs (14) (3)
Repurchase of ordinary shares 0 (99,983)
Share repurchase costs 0 (17)
Net cash used in financing activities (588,497) (671,036)
Effect of exchange rate movements on cash (3,952) (7,775)
Net increase (decrease) in cash and cash equivalents 24,297 (143,055)
Cash and cash equivalents at beginning of period 288,768 752,213
Cash and cash equivalents at end of period $ 313,065 $ 609,158